Back to top
more

Adocia (ADOCY)

(Delayed Data from OTC)

$11.80 USD

11.80
NA

0.00 (0.00%)

Updated Sep 1, 2021 10:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ADOCY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Adocia [ADOCY]

Reports for Purchase

Showing records 1 - 20 ( 23 total )

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 1

04/21/2023

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 2

11/01/2022

Company Report

Pages: 4

M1Pram Shows Even More Potential for Higher BMI Patients; Reiterate Buy, Adjust Target to €11

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 3

06/22/2022

Daily Note

Pages: 3

M1Pram Offers Early Proof of Concept; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 4

02/24/2022

Company Report

Pages: 4

Adocia Presents Key 4Q21 Figures; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 5

10/29/2021

Company Report

Pages: 4

Announces €7M in Additional Financing for Obesity Program on 3Q Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 6

09/13/2021

Company Report

Pages: 5

Progress Across the Pipeline, Especially for BC Lispro in 1H21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 7

07/23/2021

Company Report

Pages: 4

Presents 2Q Earnings; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 8

04/26/2021

Company Report

Pages: 4

Adocia Reports 1Q21 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 9

03/19/2021

Company Report

Pages: 5

Validated Assets Poised for More Clinical Trials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 10

01/29/2021

Industry Report

Pages: 7

Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 11

01/27/2021

Industry Report

Pages: 15

2021 Roadmap of Key Events Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 12

01/26/2021

Daily Note

Pages: 4

Positive BC Lispro Insulin Bridging Study Clears Way For US, EU and Chinese Phase 3 Trials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 13

01/11/2021

Daily Note

Pages: 4

Adocia Unveils Pancreatic Sem Cell Therapy for T1D at H.C. Wainwright BioConnect Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 14

10/21/2020

Company Report

Pages: 5

Adocia Provides Uneventful 3Q Earnings Update; Reiterate Buy, Lower Price Target to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 15

09/17/2020

Daily Note

Pages: 4

Additional Data in T1D Further Validates Clinical Utility of M1Pram as Adocia Expands Pramlintide Portfolio; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 16

07/28/2020

Company Report

Pages: 5

Adocia Announces 1H20 Earnings Prerelease and Progress on M1Pram and BC Insulin; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 17

05/04/2020

Company Report

Pages: 5

M1Pram Shows Differentiated Effect on Weight Loss; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 18

04/24/2020

Daily Note

Pages: 4

M1Pram Shows Positive Phase 1b Data, US Patent Granted, and Additional Studies Planned

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 19

04/20/2020

Company Report

Pages: 4

M1 Pram Data Coming This Month; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Adocia

Industry: Medical - Biomedical and Genetics

Record: 20

03/13/2020

Company Report

Pages: 4

Pressing Ahead With the Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party